Mark McClung
Net worth: 56 033 $ as of 30/04/2024
Profile
Mark D.
McClung worked as the VP & General Manager-Global Oncology Commercial at Amgen, Inc. from 2015 to 2019.
He also worked as the Chief Commercial Officer & Senior Vice President at Onyx Pharmaceuticals, Inc. He is currently the Chief Operating Officer & Executive Vice President at Sangamo Therapeutics, Inc. from 2020 to 2024.
McClung completed his undergraduate degree from York University and the University of Guelph.
He also completed an undergraduate degree from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 25/11/2023 | 111,397 ( 0.05% ) | 56 033 $ | 30/04/2024 |
Former positions of Mark McClung
| Companies | Position | End |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Chief Operating Officer | 02/01/2024 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | - |
Training of Mark McClung
| University of Guelph | Undergraduate Degree |
| York University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 1 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
- Stock Market
- Insiders
- Mark McClung
